Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hebbar

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
British Journal of Cancer|January 13, 2006
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'J Bennouna, H Perrier, B Paillot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2015
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancerG Deplanque, M Demarchi, M Hebbar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIVF A Lévi, V Boige, M Hebbar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
British Journal of Cancer|January 13, 2006
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'J Bennouna, H Perrier, B Paillot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2015
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancerG Deplanque, M Demarchi, M Hebbar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIVF A Lévi, V Boige, M Hebbar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trialM Hebbar, B Chibaudel, T André, et al.
Pageof 8